EGFR and breast cancer: For example, Schoeberl et al. explored the optimal way to therapeutically inhibit ligand-induced activation of the ERBB–PI3K axis [36], while Imoto et al. analyzed the drug sensitivity in the ERBB–MAPK–PI3K signaling network in breast cancer patients and included a proliferation/survival analysis [37].